Overview

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Status:
Completed

Trial end date:
2018-09-14

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.

Phase:

Phase 3

Details

Lead Sponsor:

CTI BioPharma

Treatments:

Gemcitabine
Pixantrone
Rituximab